Safety of NXY-059 for the Treatment of Patients who have Suffered from a Stroke
Study identifier:SA-NXY-0012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients with Acute Intracerebral Hemorrhage (ICH)
Medical condition
Intracerebral Hemorrhage
Phase
Phase 2
Healthy volunteers
No
Study drug
NXY-059
Sex
All
Actual Enrollment
600
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2004
Primary Completion Date: 01 Jan 2006
Study Completion Date: 01 Jan 2006
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca NXY-059 Medical Science Director
AstraZeneca
